These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 17721094)

  • 1. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
    Mocroft A; Ledergerber B; Zilmer K; Kirk O; Hirschel B; Viard JP; Reiss P; Francioli P; Lazzarin A; Machala L; Phillips AN; Lundgren JD;
    AIDS; 2007 Sep; 21(14):1867-75. PubMed ID: 17721094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
    Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
    AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study.
    Lundgren JD; Mocroft A; Gatell JM; Ledergerber B; D'Arminio Monforte A; Hermans P; Goebel FD; Blaxhult A; Kirk O; Phillips AN;
    J Infect Dis; 2002 Jan; 185(2):178-87. PubMed ID: 11807691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
    Kowalska JD; Reekie J; Mocroft A; Reiss P; Ledergerber B; Gatell J; d'Arminio Monforte A; Phillips A; Lundgren JD; Kirk O;
    AIDS; 2012 Jan; 26(3):315-23. PubMed ID: 22112597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
    An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.
    Podlekareva D; Mocroft A; Kirk O; Reiss P; Aldins P; Katlama C; Kovari H; Stellbrink HJ; D'Arminio Monforte A; Lundgren JD;
    Scand J Infect Dis; 2008; 40(11-12):908-13. PubMed ID: 18609197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
    Reekie J; Mocroft A; Sambatakou H; Machala L; Chiesi A; van Lunzen J; Clumeck N; Kirk O; Gazzard B; Lundgren JD;
    AIDS; 2008 Nov; 22(17):2381-90. PubMed ID: 18981778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
    Kousignian I; Abgrall S; Grabar S; Mahamat A; Teicher E; Rouveix E; Costagliola D;
    Clin Infect Dis; 2008 Jan; 46(2):296-304. PubMed ID: 18171266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
    Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
    Cozzi-Lepri A; Phillips AN; Ruiz L; Clotet B; Loveday C; Kjaer J; Mens H; Clumeck N; Viksna L; Antunes F; Machala L; Lundgren JD;
    AIDS; 2007 Mar; 21(6):721-32. PubMed ID: 17413693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
    Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
    AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
    Mary-Krause M; Billaud E; Poizot-Martin I; Simon A; Dhiver C; Dupont C; Salmon D; Roudiere L; Costagliola D;
    AIDS; 2006 Aug; 20(12):1627-35. PubMed ID: 16868444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia and survival in human immunodeficiency virus.
    Lundgren JD; Mocroft A
    Clin Infect Dis; 2003; 37 Suppl 4():S297-303. PubMed ID: 14581998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
    Seminari E; De Silvestri A; Boschi A; Tinelli C
    AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival.
    Costello C; Nelson KE; Suriyanon V; Sennun S; Tovanabutra S; Heilig CM; Shiboski S; Jamieson DJ; Robison V; Rungruenthanakit K; Duerr A
    Int J Epidemiol; 2005 Jun; 34(3):577-84. PubMed ID: 15737969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
    Mocroft A; Ledergerber B; Viard JP; Staszewski S; Murphy M; Chiesi A; Horban A; Hansen AB; Phillips AN; Lundgren JD;
    J Infect Dis; 2004 Dec; 190(11):1947-56. PubMed ID: 15529259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.
    Mocroft A; Kirk O; Clumeck N; Gargalianos-Kakolyris P; Trocha H; Chentsova N; Antunes F; Stellbrink HJ; Phillips AN; Lundgren JD
    Cancer; 2004 Jun; 100(12):2644-54. PubMed ID: 15197808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.